London, United Kingdom - February 9, 2016, London, United Kingdom - Advanced Oncotherapy, a developer of medical technology for cancer treatment, decided to realign the roles and responsibilities of the executive team.
Article continues below
Michael Sinclair, currently Executive Chairman, will become Chief Executive Officer and Executive Chairman.
Dr. Sinclair qualified in medicine from the Middlesex Hospital, London in 1967 and held a number of appointments at teaching hospitals in London. He became a Registrar in Psychiatry at the Maudsley Hospital and Institute of Psychiatry of London University before entering business in 1971.
Between 1971 and 1977 Dr. Sinclair held senior board positions with Allied Investments Limited, which had operating interests in nursing homes through Nestor Nursing Homes, nursing agencies through the British Nursing Association, deputising services for doctors, medical equipment distribution, the management of hospitals for governments in the Middle East and the operation of a health spa.
In 1979, Dr. Sinclair founded Sinclair Montrose Trust Limited as a private investment vehicle for him and his family. Her was chairman and founder of Lifetime Corporation Inc and serves on the Board of Overseers (emeritus) of the Tufts University School of Medicine.
Dr. Sinclair was also the chairman and founder of U.S.- based Atlantic Medical Management LLP, which managed the New York based healthcare venture fund, Atlantic Medical Capital LP. He is the Chairman of Lightlake Therapeutics Inc.
Sanjeev Pandya, currently Chief Executive Officer, will become Executive Vice President for Global Business Development and will remain on the Board of the Company.
Mr. Pandya joined the Company in October 2013 as COO after working as a consultant for special projects. He trained and practised as an orthopaedic surgeon in the NHS and the Third World before working as a strategy consultant with McKinsey & Company.
Mr. Pandya then spent two years at Pfizer Global Pharmaceuticals division before joining Lehman Brothers as an investment banker in healthcare M&A. More recently he has worked as an independent consultant in Russia and at Bupa in London. He has a medical degree from Trinity College, Cambridge and an MBA from INSEAD.
Nicolas Serandour, currently Chief Financial Officer, will become Chief Operating and Financial Officer.
Mr. Serandour joined Advanced Oncotherapy in September 2014 as Chief Financial Officer. He has over 15 years of experience in the investment banking industry, having worked at JP Morgan, Lehman Brothers and Lazard, where he was responsible for coordinating the European Healthcare sector coverage. ■